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Abstract
Background: During HIV infection and/or antiretroviral therapy (ART), monocytes and macrophages exhibit a wide
range of dysfunctions which contribute significantly to HIV pathogenesis and therapy-associated complications.
Nevertheless, the molecular components which contribute to these dysfunctions remain elusive. We therefore
applied a parallel approach of genome-wide microarray analysis and focused gene expression profiling on
monocytes from patients in different stages of HIV infection and/or ART to further characterise these dysfunctions.
Results: Processes involved in apoptosis, cell cycle, lipid metabolism, proteasome function, protein trafficking and
transcriptional regulation were identified as areas of monocyte dysfunction during HIV infection. Individual genes
potentially contributing to these monocyte dysfunctions included several novel factors. One of these is the
adipocytokine NAMPT/visfatin, which we show to be capable of inhibiting HIV at an early step in its life cycle.
Roughly half of all genes identified were restored to control levels under ART, while the others represented a
persistent dysregulation. Additionally, several candidate biomarkers (in particular CCL1 and CYP2C19) for the
development of the abacavir hypersensitivity reaction were suggested.
Conclusions: Previously described areas of monocyte dysfunction during HIV infection were confirmed, and novel
themes were identified. Furthermore, individual genes associated with these dysfunctions and with ART-associated
disorders were pinpointed. These genes form a useful basis for further functional studies concerning the
contribution of monocytes/macrophages to HIV pathogenesis. One such gene, NAMPT/visfatin, represents a
possible novel restriction factor for HIV.
Background: Both macrophages and T lymphocyte subsets express the CD4 receptor and either the CXCR4 and/or
the CCR5 coreceptor which confer susceptibility to infection with the Human Immunodeficiency Virus (HIV). Upon
infection, CD4+ T lymphocytes typically succumb to the cytopathic effect of the virus [1], and the gradual
depletion of the CD4+ T lymphocyte pool has been considered a hallmark of HIV infection and the development
of the Acquired Immune Deficiency Syndrome (AIDS) since the early days of the HIV pandemic. Macrophages, on
the other hand, do not tend to suffer from the cytopathic effects mediated by the virus [2,3], but instead develop
a wide array of dysfunctions which contribute significantly to the pathogenesis of HIV infection. Despite the
recognition of macrophage contribution to HIV pathogenesis early on in HIV research [4,5], most studies have
focused and continue to focus on T lymphocyte depletion and/or dysfunction, and many of the molecular
mechanisms underlying the macrophage dysfunction during HIV infection remain poorly characterised.
Nevertheless, as pointed out by other authors [6], in the combination Antiretroviral Therapy (ART) era where viral
suppression in T lymphocytes is increasingly more efficient, the understanding of the viral mechanisms in other
reservoir cells such as macrophages becomes ever more crucial.
Aberrant HIV-induced macrophage behaviour can be classified as relatively straightforward loss of function, such as
reduced phagocytosis [7,8] and antigen presentation [9], or as more complex dysfunction. Such dysfunctions
include a direct contribution to the establishment, spread and persistence of the infection: as long-living primary
target cells of HIV with a wide-spread dissemination and a persistent failure to enter apoptosis upon infection
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[10,11], they represent an important cellular reservoir for the virus [12]. Additionally, macrophages exacerbate dis-
ease progression by contributing to T lymphocyte depletion: HIV infected macrophages have been documented to
participate in the killing of uninfected CD4+ and CD8+ T lymphocytes, while at the same time protecting infected
CD4+ T lymphocytes from apoptosis [13]. Furthermore, infected and uninfected macrophages can contribute to
sustained chronic immune activation during HIV infection, e.g. through the perturbation of cytokine and chemo-
kine networks [14-16]. With the acknowledged notion of chronic immune activation as a paradoxical driving force
of immune suppression [17], this pro-inflammatory macrophage phenotype during HIV infection may be a crucial
parameter in disease progression. Yet other macrophage dysfunctions are associated with more peripheral HIV- or
ART-associated disorders such as atherosclerosis [18], lipodystrophy [19], and metabolic syndrome during HIV infec-
tion and/or combination ART [20,21].
Monocytes, for their part, are much less permissive to infection with HIV, both in vitro [22] and in vivo, where esti-
mates of infected circulating monocytes are consistently low [23,24]. Circulating monocytes represent the most
accessible primary model for macrophage dysfunction during HIV infection, however, and are furthermore of suffi-
cient importance to study in their own right. Infectious virus can be recovered from circulating monocytes, both in
untreated patients [24] and in patients undergoing long-term successful combination ART [25]. Additionally, the cir-
culating monocyte pool as a whole does seem to be affected during HIV infection, despite the low frequency of
actually infected monocytes. Transcriptome studies, in particular, show a form of hybrid phenotype exhibiting both
increased and decreased pro-inflammatory features [26,27]. This modulation of the non-infected monocyte popula-
tion could be due to the virus itself through mechanisms which do not require direct infection [28], or to other
factors contributing to (aberrant) immune activation occurring during HIV infection, such as perturbed cytokine
networks [29] or other inflammatory stimulants [30].
Several key factors in the described dysregulated processes have been identified [18,31], but many molecular com-
ponents remain elusive. Furthermore, other aspects of HIV and combination ART pathogenesis in which monocyte/
macrophage dysfunction is involved may only now be emerging or remain yet to be discovered, in particular in
view of the limited number of studies focussing on the monocyte response to ART [32]. In order to generate novel
hypotheses rather than test pre-existing ones in the context of monocyte-HIV interactions, we performed a tran-
scriptome analysis on monocyte samples from patients in different stages of HIV infection and/or combination ART
treatment, using a parallel approach of genome-wide microarray analysis and focused gene expression profiling to
identify broad areas of monocyte dysfunction and to pinpoint genes which are potentially involved in one or sev-
eral of these dysfunctions. In particular the factors which are exploited by the monocyte/macrophage to communi-
cate with and/or modulate other immune cells were of interest, as they represent a particularly relevant population
[33,34] which is a primary target for intervention.
Methods
Sample collection
For the cross-sectional study on the effects of HIV infec-
tion, 50 ml blood samples were collected in EDTA-tubes
from therapy-naïve HIV-1-seropositive patients from the
HIV-Clinic of the Institute of Tropical Medicine in
Antwerp, Belgium (inclusion of all therapy-naïve sero-
positive patients, irrespective of viral load (VL) and/or
CD4+ T lymphocyte (CD4T) count; n = 29). For the long-
itudinal study on the effects of combination ART, 20 ml
blood samples were collected in EDTA-tubes from ther-
apy-naïve patients at baseline and at 3, 6 and 9 months
after therapy initiation (NRTI+PI regimen only). In all
patients but one the indication for ART was a decline in
CD4T ≤ 350 cell/mm>3; irrespective of VL (n = 16). As
controls, 50 ml blood samples were collected in EDTA-
tubes from self-asserted HIV seronegative blood donors
without apparent infections, in the same age range as the
HIV patients (n = 15). The study was approved by the
Institutional Review Board of the Institute of Tropical
Medicine, and written informed consent was obtained
from all donors. Patient characteristics are shown in
table 1 (cross-sectional) and table 2 (longitudinal).
Peripheral blood mononuclear cells (PBMC’s) were
separated by Lymphoprep (Axis Shield, Dundee, United
Kingdom) gradient. Monocytes were purified from the
PBMC fraction using the negative selection-based
Monocyte Isolation Kit II from Miltenyi-Biotec (Ber-
gisch Gladbach, Germany), according to the manufac-
turer’s instructions. Yields were minimally 5 million
monocytes with a purity > 85%, as verified through flow
cytometry. For RNA extraction, monocytes were imme-
diately lysed in Trizol (Invitrogen, Carlsbad, CA, USA)
and lysates were stored at -80°C.
RNA and protein isolation
Total RNA was prepared from Trizol lysates by chloroform
extraction, as per the manufacturer’s recommendations.
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Ten randomly selected samples were checked for
integrity on a BioAnalyzer (BioRad, Hercules, CA, USA): no
contamination or degradation of RNA was detected.
Subsequently, the protein fraction was purified from
the Trizol pellets by isopropanol precipitation, again
according to the manufacturer’s instructions.
CodeLink arrays
Selected RNA samples were prepared and hybridised to
CodeLink HWG bioarrays (Amersham Biosciences, Frei-
berg, Germany; now Applied Microarrays, Tempe, AZ,
USA - http://www.appliedmicroarrays.com) by the VIB
MicroArray Facility http://www.microarrays.be. Total
RNA was controlled for integrity and purity using an
Agilent Bioanalyzer and a NanoDrop spectrophoto-
meter, respectively. All samples were of similar RNA
quality. Starting with 1 μg of total RNA, the RNA
amplification was performed by in vitro transcription
(IVT) with a biotin labeling reaction during the IVT,
according to the recommendations of the manufacturer
(Amersham Biosciences). A set of bacterial control
mRNAs was added to the RNA as controls for the IVT
reaction. The probes were purified and analyzed again
for yield (> 20 μg) and purity (260:280 nm and 260:230
nm > 1.8). 10 μg of the resulting antisense RNA was
fragmented according to the recommendations of the
manufacturer (Amersham Biosciences) and resuspended
in 260 μl of hybridization buffer.
The gene array chips were hybridized in a shaker-
incubator at 37°C at 300 rpm for 18 hours and washed
and stained with Cy5-Streptavidin according to the
recommendations of the manufacturer (Amersham Bio-
sciences). The DNA Microarray scanner of Agilent was
used for scanning and image analysis was performed
with the Codelink Expression Analysis 4.1 software.
Datasets were deposited at the EMBL-EBI repository
(accession E-MEXP-2255).
Macrophage Activation State arrays
The Macrophage Activation State (MAS) array was
developed as a focused and flexible tool for the analysis
of gene expression patterns in monocytes/macrophages
(manuscript in preparation). A collection of genes (ca.
700) associated with different macrophage activation
states was compiled, using a combination of literature
data-mining and human ‘translation’ of murine models
of macrophage activation available in our laboratory (the
complete gene population represented on this array is
documented in Additional file 1). Subsequently, gene
specific primers were designed for the genes in this col-
lection and fragments were amplified from total cDNA
pools of monocytes under various in vitro and in vivo
conditions. These fragments were applied in duplicate
on 7 × 10 cm nylon membranes and were cross-linked
to the membranes using UV-exposure.
RNA samples from all patients were selected for ana-
lysis on this MAS array. A reverse transcription was per-
formed on 1 μg total RNA using oligo-dT and
Superscript II reverse transcriptase (Invitrogen) in the
presence of 33P-dCTP (Amersham Biosciences), and the
labelled cDNA was then hybridised to the membranes
for 20 h at 42°C in NorthernMax hybridisation buffer
(Ambion, Austin, TX, USA). Membranes were subse-
quently washed with SDS-containing buffer at 68°C and
were exposed to a phosphorscreen to reveal bound
radioactivity. Phosphorscreens were then scanned in a
phospho-imager (BioRad). Spot recognition and quanti-
fication, background correction and array normalisation
Table 1 Clinical information of therapy-naïve HIV-1 seropositive donors (cross-sectional study)
Patient ID Experiment CD4T count
(cells/mm3)
VL (log copies/ml) Patient ID Experiment CD4T count
(cells/mm3)
VL (log copies/ml)
TN 01 MAS & CL 133 2.70 TN 16 MAS 503 4.32
TN 02 MAS & CL 142 2.28 TN 17 MAS 532 4.78
TN 03 MAS & CL 197 5.91 TN 18 MAS 535 4.78
TN 04 MAS 226 5.59 TN 19 MAS 540 4.36
TN 05 MAS 233 5.59 TN 20 MAS & CL 644 4.34
TN 06 MAS 311 4.97 TN 21 MAS 738 5.58
TN 07 MAS 329 5.37 TN 22 MAS 746 4.90
TN 08 MAS & CL 359 3.87 TN 23 MAS & CL 748 5.54
TN 09 MAS 359 5.84 TN 24 MAS 756 5.07
TN 10 MAS 371 3.60 TN 25 MAS 760 3.93
TN 11 MAS 374 4.24 TN 26 MAS 778 5.00
TN 12 MAS 382 4.00 TN 27 MAS 781 3.50
TN 13 MAS 436 4.28 TN 28 MAS & CL 856 4.82
TN 14 MAS & CL 446 3.91 TN 29 MAS 1026 3.08
TN 15 MAS 462 4.06
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were performed using custom-designed software based
on the program ImageJ (Image Processing and Analysis
in Java, Sun Microsystems, Santa Clara, CA, USA).
Real-time semi-quantitative PCR
mRNA expression of the individual genes of interest was
examined using real-time semi-quantitative PCR (RT-
qPCR). cDNA was prepared from 1 μg total RNA using
oligo-dT and Superscript II reverse transcriptase (Invi-
trogen). Gene specific primers for the genes of interest
and the housekeeping gene GAPDH (Entrez GeneID:
2597) were used to run PCR reactions in duplicate in a
BioRad MyCycler, with BioRad iQ SYBR Green Super-
mix. Gene expression was normalised using GAPDH
as a housekeeping gene. Sequences of the gene specific
primers are supplied as Additional file 2.
In vitro infection experiments
For in vitro infection experiments, PBMC’s were sepa-
rated by Lymphoprep (Axis Shield, Dundee, United
Kingdom) gradient from buffy coats of healthy donors
of the Blood.
Transfusion Centre of Antwerp and were either
employed as such in PBMC infection experiments or
were used for monocyte preparation. Monocytes were
purified from PBMC by magnetic isolation using CD14
microbeads (Miltenyi-Biotec) according to the manufac-
turer’s instructions. Yields were minimally 50 million
monocytes with a purity > 98%, as verified through flow
cytometry. These cells were then differentiated to mono-
cyte-derived macrophages (MDM) during 7 days in
RPMI 1640 medium (Bio-Whittaker, Verviers, Belgium)
supplemented with 10% bovine fetal calf serum (Bio-
chrom, Berlin, Germany), penicillin (100 U/ml) and
streptomycin (100 μg/ml) (Roche) and 40 ng/ml M-CSF
(PeproTech, London, United Kingdom) at 37°C and
5.0% CO2. Half of the medium was replaced after 4 days
of culture. Cells were harvested and used for experi-
ments in the same medium (without M-CSF). All
experiments were repeated with cells from three inde-
pendent donors.
Virus stocks (HIVBaL, HIV968-2 and HIV968-3) were
prepared by short-term propagation in PHA/IL2-stimu-
lated PBMC from HIV seronegative donors as described
previously [35].
Recombinant factors (CCL2, NAMPT and PDGFC)
were obtained from PeproTech; viability of cells treated
with the recombinant factors was evaluated using the
cell proliferation agent WST-1 (Roche) according to the
manufacturer’s instructions: no appreciable effect on cell
viability was observed at the concentrations used (data
not shown). For infections, MDM or non-activated
PBMC were plated in 96-well plates at 7.5 × 105 cells/ml
and pre-treated with recombinant CCL2 (20 ng/ml),
NAMPT (100 ng/ml) or PDGFC (20 ng/ml) for
24 hours at 37°C and 5.0% CO2. Then, a dilution series
of virus was added in sixfold and incubated for
24 hours, again at 37°C and 5.0% CO2. Cells were then
washed 3 × to remove unbound virus and incubated for
14 days in the presence of 5 ng/ml IL2 (Roche) and
0.5 μg/ml phytohemagglutinin (PHA; Murex Biotech
Ltd., Dartford, United Kingdom) for PBMC and in
Table 2 Clinical information of HIV-1 seropositive donors on combination ART (longitudinal study)
CD4T count (cells/mm3) VL (log copies/ml)
Patient ID Experiment BL M3 M6 M9 BL M3 M6 M9
HA 01 MAS 239 373 407 502 4.61 2.37 < 1.70 < 1.70
HA 02 MAS 153 222 353 263 5.36 1.75 1.85 < 1.70
HA 03 MAS 193 441 446 437 5.36 2.84 1.72 2.05
HA 04 MAS 273 608 577 761 4.58 < 1.70 < 1.70 < 1.70
HA 05 MAS 548 592 956 778 4.88 2.12 < 1.70 < 1.70
HA 06 MAS 239 317 348 591 5.01 < 2.60 < 1.70 < 1.70
HA 07 MAS 165 209 282 222 5.13 < 2.60 < 2.60 < 1.70
HA 08 MAS 146 241 264 315 4.48 < 1.70 < 1.70 < 1.70
HA 09 MAS 205 ND 400 318 5.45 ND < 1.70 < 1.70
HA 10 MAS 269 327 451 372 5.26 < 1.70 < 1.70 < 1.70
HA 11 MAS 324 707 561 590 5.68 3.26 < 2.60 < 2.60
HA 12 MAS 202 245 254 242 5.16 < 1.70 < 1.70 < 1.70
HA 13 MAS 261 ND 425 432 5.77 ND < 1.70 < 1.70
HA 14 MAS 318 257 270 338 5.14 < 1.70 < 1.70 < 1.70
HA 15 MAS 258 524 462 300 4.57 2.35 < 1.70 < 1.70
HA 16 MAS 232 356 358 318 5.57 < 2.60 3.85 < 1.70
MAS: custom Macrophage Activation State array platform; CL: commercial CodeLink HWG bioarray platform; CD4T: CD4+ T lymphocyte; VL: viral load; BL: baseline;
M3/6/9: sample taken resp. 3, 6 and 9 months after therapy initiation; ND: not done.
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complete medium without cytokines for macrophages.
Productive infection was monitored via an in-house
developed p24 antigen ELISA, as described elsewhere
[35]. Viral infectivity was quantified as the TCID50 (50%
tissue culture infectious dose) value, which was calcu-
lated by the method of Reed & Muench [36]. For viral
binding experiments, the same procedure was followed
(pre-incubation with NAMPT of 4 hours instead of
24 hours), but cells were incubated with the virus for
2 hours and were then lysed in 200 μl NP40 solution
after washing. p24 content of the lysate was then
assessed by ELISA to quantify the bound virus.
For proviral quantification experiments, MDM or
non-activated PBMC were plated in 24-well plates at
1 × 106 cells/ml and pre-treated with recombinant vis-
fatin (200 ng/ml) for 24 hours at 37°C and 5.0% CO2.
Then, virus was added at a multiplicity of infection of
0.1 and 0.001 and incubated for 24, again at 37°C and
5.0% CO2. Cells were then immediately lysed in Trizol
(Invitrogen) and genomic DNA was prepared from the
Trizol pellets as per the manufacturer’s recommenda-
tions. Proviral DNA levels were determined semi-quan-
titatively by RT-qPCR: gene specific primers for the
viral LTR region (LTR_NEC152: 5′-GCCTCAATA
AAGCTTGCCTTGA-3′ and LTR_NEC131: 5′-GGC
GCCACTGCTAGAGATTTT-3′) and the genomic
housekeeping fragment ERV-3 (PHP10-F: 5′-CATGG
GAAGCAAGGGAACTAATG-3′ and PHP10-R: 5′-CC
CAGCGAGCAATACAGAATTT-3′) were used to run
PCR reactions in duplicate in a BioRad MyCycler, with
BioRad iQ SYBR Green Supermix. Proviral DNA was
normalised using ERV-3 as a housekeeping gene, as
discussed elsewhere [37].
Nampt-Elisa
An ELISA kit for NAMPT/visfatin (AdipoGen, Seoul,
Korea) was used for NAMPT detection, as suggested by
Körner and colleagues [38]. Plasma samples (undiluted)
of HIV patients and healthy control donors were ana-
lysed according to the manufacturer’s instructions.
NAMPT-Western Blot
Total cellular NAMPT was detected by Enhanced
Chemoluminescence (ECL) Western Blot. 30 μg samples
were run on a 10% SDS-PAGE gel and transferred to
PVDF membranes using the iBlot Dry Blotting System
(Invitrogen) according to the manufacturer’s instruc-
tions. A rabbit anti-NAMPT polyclonal Ab (Bethyl
Laboratories, Montgomery, TX, US) at 1:3000 dilution
and an an anti-rabbit-HRP conjugate (Sigma-Aldrich,
Saint Louis, MO, US) at 1:10000 dilution were used to
probe these membranes. The membranes were subse-
quently incubated for 5 minutes with SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL,
US) and exposed to photosensitive film. Films were
developed using a Fujifilm FPM-100A developer (Fuji-
film, Tokyo, Japan). After exposure, the membranes
were incubated in 50% H2O2 to saturate the bound HRP
and were reprobed in the same fashion for the house-
keeping protein b-actin.
In vitro assessment of NAMPT activity
MDM generated as described above, plated in 96-well
plates at 7.5 × 105 cells/ml, were stimulated with
NAMPT (200 ng/ml) and E. coli lipopolysaccharide
(LPS) (100 ng/ml) for 2 days. Secretion of the b-chemo-
kines MIP1a (CCL3), MIP1b (CCL4) and RANTES
(CCL5) was assessed by Cytometric Bead Assay (CBA)
(Becton Dickinson, Erembodegem, Belgium) in cell cul-
ture supernatants according to the manufacturer’s
instructions. Additionally, CCR5 and CXCR4 expression
on stimulated MDM was assessed in flow cytometry as
described previously [39].
Statistical analysis
All microarray datasets were processed using the Gene-
Maths XT software package (Applied Maths, St.-Mar-
tens-Latem, Belgium).
For CodeLink HWG bioarrays, all genes were re-anno-
tated (i.e. updating of replaced Gene ID’s, etc.) using the
22.01.2009 releases of the Entrez and UniGene data-
bases. A dataset was compiled after background correc-
tion (subtract algorithm) and array normalisation (mean
algorithm). A set of differentially expressed genes was
compiled by filtering the data according to three criteria:
(1) statistical significance: p-value as determined by
Student’s t test < 0.01 (or for a more stringent analysis:
p-value after Benjamini-Hochberg correction [40] for
FDR control < 0.1); (2) reliability: a spot quality flag G
(“good”, a quality flag assigned by the CodeLink soft-
ware package) in all arrays and (3) relevance: a fold
change between the means of the two groups ≥ 1.5.
Overrepresentation analysis was performed on pro-
cessed CodeLink datasets using the application Gene
Map Annotator and Pathway Profiler (GenMAPP) [41]
v.2.1 and the associated program MAPPFinder [42]
v.2 (based on the Gene Ontology (GO) annotations pro-
vided by the GO Consortium[43]). Pathways which were
identified by these software packages were subjected to
filtering criteria: (1) number of “changed” (i.e. signifi-
cantly differentially expressed) genes in a pathway ≥ 3;
(2) z-score ≥ 1.96 and (3) permute p-value ≤ 0.05.
For MAS arrays, datasets were compiled as mentioned
above. Sets of differentially expressed genes were com-
piled by filtering the data according to (1) statistical sig-
nificance: p-value as determined by an uncorrected
Mann-Whitney test < 0.05 (for the cross-sectional study)
or a p-value < 0.05 in ANOVA (for the longitudinal
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study); (2) reliability: variation between spot replicates
≤ 20% and (3) relevance: a fold change between the
means of two groups (HIV versus controls or ART base-
line versus ART timepoints) ≥ 1.5. The error rate was
estimated by RT-qPCR and training/comparison set vali-
dation, using the cross-sectional study as training set and
the baseline samples of the longitudinal study as compar-
ison set. For the smaller population sizes in the analysis
of genes associated with the abacavir hypersensitivity
reaction, an uncorrected Student’s t-test and a more
stringent fold change cut-off of 2.5 were used to identify
differentially expressed genes.
Correlation of gene expression with viral load and/or
CD4T count was assessed via Spearman correlation test.
All viral infection data are expressed as mean ± SEM;
representative data of at least three independent experi-
ments are shown, except where indicated. NAMPT
expression data and plasma loads were assessed by non-
parametric Mann-Whitney test.
Results
Identification of perturbed gene networks in monocytes
of therapy-naïve HIV patients
To identify the areas of monocyte dysfunction in our
patient population, eight therapy-naïve HIV patient sam-
ples and four healthy control samples (table 1) were
selected for analysis on CodeLink HWG microarrays.
Samples with a broad range of CD4T counts representa-
tive for the full patient population, and healthy controls
in the same age range, were chosen. While the sample
number in this preliminary experiment was too low to
identify reliable individual biomarkers with sufficient
statistical power, these datasets can be used to distin-
guish the broad cellular processes or pathways which
are modulated as a whole by HIV infection. Samples
were grouped according to HIV sero-status, i.e. no stra-
tifications according to CD4T count or viral load were
performed. A collection of 91 differentially expressed
genes (172 using the less stringent conditions) was com-
piled (supplied as Additional file 3).
The processed datasets were then analysed using Gen-
MAPP and MAPPFinder to identify the global biological
trends in our expression data. This over representation
analysis revealed a set of processes which appear to be
modulated/dysregulated to a significant degree in mono-
cytes of therapy-naïve HIV patients (table 3). The most
specific GO term which is still significant is shown: i.e.
when for example “regulation of transcription” and its
daughter term “negative regulation of transcription” are
called as significant, we show only this second term.
Several of these processes, such as transcriptional regu-
lation and cell cycle modulation, were previously identi-
fied in other transcriptome studies as modulated by HIV
in monocytes and monocyte-derived macrophages
(MDM) (reviewed in e.g. [32]). Others, such as lipid
metabolism and proteasome function, have been linked
with HIV-monocyte/macrophage interactions [18,44],
but were to the best of our knowledge not yet described
in the context of a transcriptome analysis. Establishment
of these broad areas of gene dysregulation in monocytes
during HIV infection allowed us to classify genes in our
subsequent analyses.
Focused transcriptome profiling of monocytes of therapy-
naïve and combination ART-treated HIV patients
In parallel with this pathway-finding approach, we
attempted to identify individual differentially expressed
genes in a cross-sectional study of therapy-naïve HIV
patients and in a longitudinal study of HIV patients on
combination ART (table 1&2) using our custom MAS
array platform. The cross-sectional group of therapy-
naïve HIV patients was used as a training set: the gene
expression in this population (n = 29) was compared
with the expression in healthy control samples (n = 15)
in order to identify genes with a differential expression
between the groups, using our filtering criteria described
above (significance/reliability/relevance). Furthermore,
subgroups of patients with a high plasma viral load (VL
≥ 5 log copies/ml, n = 9) and/or a low CD4 T count
(CD4 T ≤ 400 cells/mm3, n = 12) only were also com-
pared with healthy control samples. The genes passing
our selection (31 transcripts or 30 genes) were validated
by RT-qPCR. Gene normalisation was performed using
GAPDH expression. While several studies have sug-
gested that GAPDH is suboptimal as a housekeeping
gene in specific models (e.g. [45]) and that the enzy-
matic pathway in which it is involved may be modulated
by HIV infection [46], our own analyses on several
archetypal housekeeping genes indicated that GAPDH
was stably expressed across all samples (not shown). In
this way, we were able to compile a collection of genes
(29 transcripts, 28 genes) for which the expression was
associated with HIV serostatus in the training set of
therapy-naïve samples.
This collection of genes was then validated against the
comparison set of baseline samples of the longitudinal
study, which were analysed in the same fashion (MAS
array profiling followed by RT-qPCR confirmation). 26
transcripts (25 genes) passed this validation (Figure 1A,
references [47-57]), while 6 additional genes were found
in the comparison set which were not identified in the
training set. Furthermore, in the training set two addi-
tional genes were identified only in patients with high
VL and/or low CD4T count (Figure 1B), while in the
comparison set two genes modulated exclusively by
therapy were identified by ANOVA (Figure 1C, refer-
ence [58]). For 14 of these transcripts expression was
restored to control levels, while for 12 the expression
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remained dysregulated after 9 months of combination
ART. An overview of the different classes of genes is
presented in table 4.
Identification of genes associated with the abacavir
hypersensitivity reaction
In the longitudinal arm of this study, we observed a
hypersensitivity reaction to the drug abacavir in two out
of seven patients, at the time unscreened for HLA-
B*5701, who were receiving abacavir as a component of
their combination ART regimen. Using our MAS array
dataset, we compared monocyte gene expression pat-
terns at baseline between patients with the hypersensi-
tivity reaction and patients on the same regimen
without adverse effects. We identified 6 genes which
appear to be differentially expressed between patients
who develop the abacavir hypersensitivity reaction and
patients who do not: the cytoplasmic enzymes CA2 and
CYP2C19, the chemokine CCL1, the transcription factor
NFIB, and the transmembrane receptor NRP2 were
upregulated in these patients, while the uncharacterised
nuclear factor ANP32E was downregulated (Additional
file 4). While these results lack statistical power due to
the small population sizes, they are indicative of trends
which may be of particular interest in the context of
monocyte involvement in the hypersensitivity reaction
or in the pursuit of biomarkers with diagnostic or prog-
nostic value.
Upregulation of an innate immune factor with inhibitory
capacities against HIV
As mentioned previously, we were particularly interested
in secreted factors which are used by the monocyte/
macrophage to modulate their own activity or that of
other immune cells. Out of the secreted factors modu-
lated in the therapy-naïve HIV patients, CCL2 (also
known as MCP-1, Entrez GeneID 6347), NAMPT (also
known as visfatin or PBEF1, Entrez GeneID 10135) and
PDGFC (also known as fallotein, Entrez GeneID 56034),
were found to be correlated with the viral load in ther-
apy-naïve patients (Figure 2A-C) and for CCL2 a corre-
lation with the CD4T count was also observed
(Figure 2D). As a first step to evaluate the putative con-
tribution of these factors to HIV infection, non-activated
PBMC and MDM were pre-treated with these factors
and then infected with the HIV lab strain BaL. For two
out of the three factors, CCL2 and PDGFC, inconsistent
effects between individuals were observed in both
PBMC and MDM. The novel adipocytokine NAMPT,
however, significantly inhibited HIVBaL infection in all
donors in both cell-types (Figure 3A-B). Upon further
examination, NAMPT was also capable of inhibiting the
Table 3 Overrepresentation of biological processes in differential gene expression data of monocytes from therapy-
naïve HIV patients
Class GO term GO ID1 z-score2 p-value3
Apoptosis/DNA damage
induction of apoptosis 6917 2.622 0.03
response to radiation 9314 3.198 0.017
Cell cycle
cell maturation 48469 3.862 0.006
positive regulation of cell proliferation 8284 3.062 0.009
Lipid Metabolism
Hs_Adipogenesis User 2.896 0.018
Proteasome activity
cysteine-type endopeptidase activity 4197 4.486 0.009
Proteolysis 6508 1.996 0.044
ubiquitin cycle 6512 2.271 0.041
ubiquitin-protein ligase activity 4842 2.527 0.05
Protein trafficking
protein import into nucleus 6606 4.732 0.001
Transcriptional regulation
DNA binding 3677 2.929 0.003
negative regulation of transcription 16481 3.207 0.012
transcription regulator activity 30528 2.534 0.017
negative regulation of transcription\, DNA-dependent 45892 2.422 0.038
GO: Gene Ontology; 1: the official GO identification code for the process http://www.geneontology.org, “User” denotes a user contributed pathway; 2: the score
for the standard statistical test under the hypergeometrical distribution, as calculated by MAPPFinder; 3: the permute p-value as correction on the z-score, as
calculated by MAPPFinder; GO terms shown in boldface were identified using both the stringent and less stringent criteria, other terms were only found using
the less stringent criteria.
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Figure 1 Genes identified by transcriptome analysis in monocytes of HIV patients versus healthy controls. A) Genes passing RT-qPCR
and training/comparison set validation; mean fold change between the comparison set and healthy controls as assessed by RT-qPCR is shown
at baseline and at 3, 6 and 9 months of therapy. 1: the Official Gene Symbol (OGS, Entrez Gene); 2: the Entrez Gene identification code; 3:
Classification system (evidence for these classifications was derived from the Gene Ontology annotations, except where indicated); B) Genes
identified only in patients with CD4T ≤ 400 cells/mm3 and/or VL ≥ 5 log copies/ml; mean fold change between the comparison set and healthy
controls as assessed by RT-qPCR is shown at baseline and at 3, 6 and 9 months of therapy. C) Genes identified by ANOVA as differentially
regulated during therapy; mean fold change between the comparison set and healthy controls as assessed by RT-qPCR is shown at baseline and
at 3, 6 and 9 months of therapy.
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Table 4 Classification of differentially expressed genes in monocytes of therapy-naïve and combination ART-treated
HIV patients
Modulated by HIV, persistent Modulated by HIV, reversible Modulated by ART
OGS1 Entrez ID2 OGS1 Entrez ID2 OGS1 Entrez ID2
Down NR0B2 8431 IL1F7 27178 GAS6 2621
MAFF 23764 ADORA2A 135 CAPZA1 829
SLC11A1 6556 CCL23 6368
IL8 3576 CCL4L1 9560
CX3CR1 1524
CAPG 822
CCR2 729230
LILRB4 11006
CXCL2 2920
Up PTGER2 5732 CD83 9308
KLF10 7071 HLA-DRA 3122
FCGR3A 2214 BCL6 604
CDKN1A 1026
MARCKS 4082
STAT1 isoform - a 6772
STAT1 isoform - b 6772
NAMPT 10135
PDGFC 56034
CCL2 6347
1: the Official Gene Symbol (OGS, Entrez Gene); 2: the Entrez Gene identification code. Genes encoding secreted factors are shown in boldface.
Figure 2 A-C) Correlation of mRNA gene expression in monocytes of therapy-naïve HIV patients, as assessed by RT-qPCR, with the
viral load; D) Correlation of mRNA gene expression in monocytes of therapy-naïve HIV patients, as assessed by RT-qPCR, with the
CD4+ T lymphocyte count - p-values for Spearman correlation testing are shown.
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biological clones HIV968-3 and HIV968-2 [59] (Figure 3C),
suggesting that the induction of this factor in monocytes
during HIV infection could represent a hitherto
unknown innate antiviral response. As plasma levels
(Figure 4A) and total monocyte protein expression of
NAMPT (Figure 4B) were also found to be elevated in
HIV patients but not in patients on > 9 months combi-
nation ART, mirroring the mRNA expression levels, this
factor may be of in vivo relevance during HIV infection.
NAMPT interferes with early events of the viral life cycle
To evaluate at which level the effect of NAMPT may be
acting, integration of proviral DNA in presence and
absence of NAMPT was measured semi-quantitatively
in HIVBaL-infected MDM and PBMC. NAMPT treat-
ment managed to decrease the integration of proviral
DNA in infected cultures (Figure 5A), suggesting that
NAMPT interferes with early, pre-integration events of
the viral life cycle. As viral binding and entry into the
cell is a likely target of inhibitory factors, we assessed
whether NAMPT could block viral interaction with the
cell. While a modest reduction of HIV attachment to
MDM was observed in a crude viral binding assay
(Figure 5B), inhibition of infectivity was not due to
modulation of CD4 (not shown) or the CCR5 coreceptor
(Figure 5C) or induction of the b-chemokines MIP1a,
MIP-1b and RANTES (Figure 5D), suggestive of a novel
inhibitory mechanism.
Discussion
Despite a clearly established role of monocytes and
macrophages in the pathogenesis of HIV infection,
the molecular mechanisms and genetic networks
underpinning the myeloid dysfunctions during HIV
infection have remained elusive. Using a combined
Figure 3 Modulation of viral infectivity of the lab-attenuated
strain HIVBaL by the secreted factors CCL2, NAMPT and PDGFC:
infection of A) PBMC and B) MDM (pre-)treated with
recombinant factors by HIVBaL. C) Modulation of the viral
infectivity of the biological clones HIV968-2 and HIV968-3 by the
secreted factor NAMPT in PBMC and MDM. TCID50 values were
determined using the method of Reed & Muench[36], based on p24
measurement in culture supernatants. Infectivity in treated cells is
expressed as a percentage of infectivity in untreated control cells.
Results in 3 independent donors are shown.
Figure 4 A) Plasma levels of NAMPT versus therapy status, as
assessed by ELISA (nControl = 13, nTherapy-naïve = 24, nART = 19);
B) Total NAMPT protein expression in monocytes of therapy-naïve
HIV patients (VL ≥ 4 log copies/ml), normalised to b-actin
expression, as assessed by ECL-Western Blot (nControl = 15,
nTherapy-naïve = 28). p-values calculated by nonparametric Mann-
Whitney test; n.s.: not significant, ART: antiretroviral therapy.
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approach of genome-wide microarray analysis and
focused monocyte/macrophage-specific gene expres-
sion profiling, we attempted to identify genes which
may contribute to the HIV-associated monocyte
dysfunction in vivo.
Using a commercial genome-wide microarray platform
we identified several biological processes which were
significantly modulated by HIV infection. These pro-
cesses include both previously documented pathways in
the context of monocyte-HIV interactions, such as cell
cycle modulation and apoptotic pathways, and processes
hitherto not identified in this context by transcriptome
profiling, such as lipid metabolism, protein trafficking
and proteasome function. Our gene expression data are
supported by previously documented in vitro studies in
these domains [18,44].
A custom monocyte/macrophage-focused gene expres-
sion profiling platform combined with RT-qPCR valida-
tion was used to identify individual genes of interest in
different areas of dysfunction in monocytes of therapy-
naïve and ART-treated HIV patients. This approach was
chosen for its higher cost-effectiveness and increased
experimental flexibility versus a commercial microarray
setup (manuscript in preparation). Our datasets reflect
an aberrant immune activation of monocytes/macro-
phages which may be of considerable relevance for HIV
pathogenesis. Specifically, we observe suppression of a
cluster of factors involved in chemotaxis, suggesting an
important deficiency at the level of immune cell recruit-
ment in monocytes of HIV infected patients (table 5).
Other immune response-associated genes are downregu-
lated as well, indicative of a deficient monocyte activa-
tion state: PLA2G7, the IL1-like cytokine IL1F7 and the
ion transporter SLC11A1, commonly known as Natural
Resistance Associated Macrophage Protein or NRAMP1.
On the other hand, the downregulation of ADORA2A
and LILRB4, and the upregulation of PTGER2, IFI30,
STAT1, CD83, BCL6 and NAMPT are suggestive of an
activated phenotype. Our results are therefore in accor-
dance with observations concerning a mixed phenotype
of both increased and decreased pro-inflammatory fea-
tures [26,27] which does not seem to be restored com-
pletely during at least the first 9 months of combination
ART. A longer period of combination ART may be
required to normalise this phenotype, or it may repre-
sent a true irreversible immune dysfunction in the
monocyte population.
Most of the genes in our collection can be clustered in
the functional categories identified in the genome-wide
analysis. As such, our approach differs from other tran-
scriptome analyses, in that we identify candidate genes
for further analysis in a broad range of categories, rather
than focussing on particular aspects of monocyte/
Figure 5 A) Levels of integrated proviral DNA in MDM and
resting PBMC (pre-)treated with NAMPT (200 ng/ml) and
infected with HIVBaL at 0.1 and 0.001 MOI, normalised to
ERV-3, as assessed by RT-qPCR; B) viral binding to MDM, as
quantified by p24 concentrations in cell lysates after 2 hours
incubation and washing of the unbound virus; C) expression of
CCR5 and CXCR4 on MDM treated 2 days with NAMPT (200 ng/ml)
and LPS (100 ng/ml), as assessed by flow cytometry[39]; D)
secretion of the b-chemokines MIP1a, MIP1b and RANTES by
MDM treated 2 days with NAMPT (200 ng/ml) and LPS
(100 ng/ml), as assessed by CBA. MFI: mean fluorescence
intensity.
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macrophage dysfunction [26,27,60]. These clusterings
are summarised in table 5.
In the context of apoptosis/DNA damage for example,
we identify a cluster of genes which may contribute to
the anti-apoptotic gene signature described in monocytes
of HIV infected patients [15,60]. A cluster of factors
which is capable of mediating apoptotic triggers in trans
on other cells, thus contributing to lymphocyte depletion,
was also identified. A similar cluster of genes possibly
involved in HIV-driven cell cycle modulation [61] and
multiple genes in the context of the broad biological
terms protein trafficking and transcriptional regulation,
reflecting the general subversion of the cellular machin-
ery for viral purposes, were also described (table 5).
Specifically in the context of metabolic disorders, our
results support the growing notion that metabolic dys-
regulation in the context of HIV infection is probably
not limited to the phase under ART, but is a pre-exist-
ing condition, manifesting sub-clinically during ther-
apy-naïve HIV infection [62,63]. We have indeed
identified a set of genes dysregulated by HIV itself
which may be capable of modulating lipid metabolism.
Downregulation of the nuclear factor NR0B2 can via
several intermediaries increase the catabolism of cho-
lesterol [64]. Downregulation of the acetylhydrolase
PLA2G7 may result in an increased risk for athero-
sclerosis, though the role of this enzyme in this field is
still contentious. The decreased expression of CCR2
[65] and increased expression of NAMPT [66,67] may
impact on atherosclerotic lesion formation. In the con-
text of ART-associated complications, finally, we have
identified several genes which are reported to be linked
with lipodystrophy and/or the metabolic syndrome as
modulated under ART (CAPZA1 [68], CCL2 [69],
GAS6 [70], NAMPT [71,72], STAT1 [73]), suggesting
that the monocyte population may contribute to the
development of ART-associated metabolic disorders
through these factors.
Additionally, the genes identified in our study may of
course play unexpected roles in other manifestations of
monocyte/macrophage dysfunction. Because of the
interesting properties of secreted factors, which repre-
sent the means by which monocytes/macrophages can
mediate many of their effects in autocrine or paracrine
fashion [29,33,34], we focused on three factors which we
identified as differential and which showed an associa-
tion with the viral load in therapy-naïve HIV patients.
For two factors, CCL2 and PDGFC, no consistent effects
were observed on HIV infectivity in PBMC and MDM.
For the novel adipocytokine NAMPT/visfatin, however,
an inhibitory effect was observed on HIV infection in
both cell types for both a lab-attenuated strain and two
biological clones. NAMPT may thus represent an (inter-
feron-induced) antiviral factor which is elicited in
response to higher levels of circulating virus. Indeed, in
silico profiling of NAMPT expression using the web
application Genevestigator [74] suggests that it is upre-
gulated in multiple models of viral infection, including
infections with CMV, measles virus, herpes simplex
virus, rotavirus and adenoviruses.
NAMPT appears to act on early events of the viral life
cycle, as the integration of proviral DNA is abrogated by
NAMPT treatment. A plausible mechanism for the inhi-
bitory activity of NAMPT would therefore be blocking
of viral binding to the cell; indeed, binding of HIV is
reduced in the presence of NAMPT. However, the
observed modest reduction may suggest that viral bind-
ing is not the only or even the most important factor in
NAMPT activity. Additionally neither modulation of
(co-)receptor expression or induction of b-chemokine
secretion by visfatin could be demonstrated. Possible
other aspects of viral binding and/or post-entry/pre-
Table 5 Functional classification of differentially expressed genes in monocytes of therapy-naïve and HIV patients
Immune
function:
chemotaxis
Immune
function:
inactivation
Immune
function:
activation
Anti-
apoptotic
(cis)
Pro-
apoptotic
(trans)
Cell cycle Protein
trafficking
Transcriptional
regulation
Metabolic
dysregulation
CCL23 ADORA2A IL1F7 ADORA2A [80] IL8 [81] CCL23 [82] CAPG MAFF CCR2 [65]
CCL4L1 LILRB4 PLA2G7 BCL6 [83] HLA-DRA [50] IL8 [84] BCL6 NR0B2 NR0B2 [64]
CCR2 SLC11A1 CCL2 [85] STAT1 [86] NR0B2 [47] MARCKS BCL6 PLA2G7
CX3CR1 BCL6 CDKN1A [87] BCL6 [88] YWHAZ CDKN1A NAMPT [66,67]
CXCL2 CD83 NAMPT [89] CCL2 KLF10
IL8 IFI30 YWHAZ [90] CDKN1A [91] STAT1
NAMPT HLA-DRA [50]
PTGER2 KLF10 [92]
STAT1 NAMPT
PDGFC
STAT1 [55]
Official Gene Symbols are shown; genes in italics are downregulated, genes in boldface are upregulated.
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integration effects remain to be evaluated. In this regard,
the role of NAMPT in TNF regulation through its func-
tion in cellular energy metabolism [75] seems a promis-
ing research avenue.
Finally, we analysed the gene expression patterns in
monocytes from patients who developed a hypersensiti-
vity reaction to abacavir, a severe and potentially lethal
adverse reaction to the drug. Compelling evidence for
the involvement of antigen presenting cells in general
and monocytes in particular in the development of the
abacavir hypersensitivity reaction was recently published
[76]. Six genes were identified as differentially expressed
at baseline between patients who developed the hyper-
sensitivity reaction and patients who were initiated on
the same regimen and had a beneficial response. These
genes may provide a first basis for investigations aimed
at the identifying bio-markers for the development of
the abacavir hypersensitivity reaction. This could be
especially useful in populations where the HLA-B*5701
genotypic screening lacks predictive value [77]. Further-
more, they may play an important role in the molecular
mechanisms underlying this detrimental form of
immunopathology. Two genes in particular may be of
functional interest: upregulation of CYP2C19, a member
of the cytochrome P450 monooxygenase family with a
reputation for antiretroviral drug interactions [78], may
lead to a higher availability of abacavir metabolites,
which may in turn trigger the hypersensitivity reaction.
Higher expression of the inflammatory chemokine
CCL1, on the other hand, is associated with so-called
M2b or type 2 alternative monocyte activation [79], and
may thus be indicative of a predisposition to allergic/
hypersensitivity reactions.
An unexplored aspect of this study is an inherent lim-
itation to all transcriptome analyses. In our setup, it can-
not be ascertained to what extent the differential genes
which we identify are dysregulated to a limited degree in
the complete monocyte population or to a high degree in
a limited monocyte subpopulation (such as only the frac-
tion of infected monocytes in the blood). However, con-
sidering the limited number of infected monocytes in the
peripheral blood, it is likely that the changes in gene
expression which we record here are the result of exter-
nal factors on the complete monocyte population (such
as circulating viral antigens or secreted host-derived fac-
tors) rather than direct infection of individual monocytes.
In this study of ex vivo monocytes from HIV patients,
we have identified several key areas of cellular dysfunction,
and we have pinpointed multiple genes associated with
both HIV infection and antiretroviral therapy in these key
areas. These genes represent an interesting population for
further in-depth functional studies concerning their role
in HIV pathogenesis. A first candidate for further func-
tional analysis could be the factor NAMPT/visfatin, which
shows a strong correlation with the viral load in patients,
and which seems to mediate an inhibitory effect for HIV
infection in both PBMC and MDM.
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